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tools [8]. Recently, Boskovic et al. [9] reported that liver biopsy
was superior to DTT in the diagnosis of BA.
As for the safety of liver biopsies, Pietrobattista et al. [10]
raised the issue asking ‘‘Is juvenile liver biopsy unsafe?’’ They
concluded that ultrasound-guided biopsy, performed in a special-
ized tertiary care paediatric centre by an experienced physician,
is considered safe; which is the same in our experience.
Although the study population in our study was relatively
small, yet, when compared to the studies (discussed in our arti-
cle) of Chiba and Kasai as well as Gupta et al., evaluating different
scores for discriminating BA, our study population was still
relatively high [1] (population size was 123, 120 and 135,
respectively). Nonetheless, we suggest that the score needs to
be validated in different populations with different investigators.
The numbers in Fig. 1C and D [1] represent the values of the
odds ratio (OR) model. For a parameter like hepatic subcapsular
ﬂow, which was found in 29/30 of BA and in 1/30 of the non-
BA (Table 3), the OR equals 841. The regression coefﬁcient for
the same parameter was 6.735 and the relative risk was 29. This
clariﬁes the higher values in the OR model compared to other
models. So, we afﬁrm that there is no mistake.
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JOURNAL OF HEPATOLOGYAST/platelet ratio index associates with progression
to hepatic failure and correlates with histological
ﬁbrosis stage in Japanese patients with primary biliary cirrhosisTo the Editor:
We read with great interest the study by Trivedi, Bruns and col-
leagues [1] on the association between the AST/platelet ratio
index (APRI) and long-term transplant-free survival in patients
with primary biliary cirrhosis (PBC). The authors demonstrated
that elevated APRI (>0.54) at diagnosis and/or 1 year afterward
(APRI-1y) was signiﬁcantly associated with a future risk of
adverse events independently and additively of the ursodeoxy-
cholic acid (UDCA) therapy response, using a deviation cohort
from the Elizabeth Hospital, Birmingham (UK), and a validation
cohort from the Toronto Center for Liver Diseases (Canada) and
the Jena University Hospital (Germany). Since APRI is a simple,
widely studied, non-invasive, and easily calculated marker of
liver disease, it represents a useful tool in clinical practice, espe-
cially at outpatient clinics, to assess patient prognosis and help
clinicians identify individuals in need of greater care.
Although the racial background of the study groups was not
described by Trivedi and Bruns [1], we presumed that the major-
ity of subjects were Caucasian according to the authors’ well
known prior studies. Racial background has been linked to the
polymorphisms of genes involved in liver disease, which are asso-
ciated with disease status, prognosis and response to UDCA ther-
apy [2–4]. Therefore, we examined the association between APRI
and progression to hepatic failure in Japanese patients with PBC
to evaluate whether APRI could be a clinical indicator of disease
outcome across multiple ethnicities.Journal of Hepatology 2014 vol. 61 j 1438–1452 1443
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Fig. 1. APRI is associated with several clinical ﬁndings. (A) AUROC curves demonstrate the accuracy of APRI at diagnosis in predicting disease progression to hepatic
failure in patients with primary biliary cirrhosis. (B) Kaplan-Meier testing indicates that patients with APRI >0.54 at diagnosis are more likely to progress to hepatic failure.
(C) APRI at diagnosis is positively correlated with hepatic ﬁbrosis in tissue sections obtained by liver biopsy. Dots indicate individual APRI values at diagnosis. Boxes
represent the interquartile range of the data. The lines across the boxes indicate median values. (This ﬁgure appears in color on the web.)
Letters to the EditorA total of 272 patients (230 women, 84.6%) who were diag-
nosed at the Shinshu University Hospital, Matsumoto, Japan, as
having PBC between 1981 and 2012 were analysed in accordance
with the principles of the Declaration of Helsinki. The genetic
background of all subjects was uniformly Japanese as described
in previous association studies [4,5]. The median age of our cohort
at diagnosis was 58 (range: 28–85) years. The follow-up period
ranged from 0.5 to 28 years with a median of 9 years. Anti-mito-
chondrial antibody (AMA) and anti-nuclear antibody were posi-
tive in 256 (94.1%) and 201 (74.0%) of cases, respectively. Liver
biopsy was performed in 192 (70.6%) patients, which histologi-
cally demonstrated Scheuer’s stage I, II, III, and IV in 121, 39, 21,
and 11 subjects, respectively. A total of 265 patients (97.4%) were
treated with UDCA during the study period. Among them, 205
(77.4%), 42 (15.8%), and 18 (6.8%) patients were given a daily dose
of 600 mg (median dose 11.1 mg/kg for a median of 8 years; Paris-
I responders: 85.6%, APRI-1y 60.54: 66.7%), 300 mg (median dose
5.8 mg/kg for 9 years; Paris-I responders: 81%, APRI-1y 60.54:
65.0%), and 900 mg (median dose 15.0 mg/kg for 5 years; Paris-I
responders: 73.3%, APRI-1y 60.54: 64.3%), respectively, according
to the recommended initial dosage of 600 mg in Japan [6]. 19
patients (7.5%) experienced disease progression to hepatic failure,
which was deﬁned as decompensated liver cirrhosis status,
including jaundice, encephalopathy, ascites, gastrointestinal
bleeding, and/or hepatorenal syndrome. 7 patients (2.6%) were
complicated with hepatocellular carcinoma. 4 patients (1.5%)
required orthotopic liver transplantation. The 5-, 10-, and 20-year
cumulative incidences of hepatic failure were 3.5%, 5.8%, and
12.7%, respectively, after Kaplan-Meier testing. The median value
of APRI at diagnosis was 0.55 (range: 0.08–8.58). When applied as
a continuous variable predictive of progression to hepatic failure,
APRI at diagnosis provided high prognostic accuracy (AUROC:
0.789, 95% conﬁdence interval: 0.742–0.835) (Fig. 1A). We
observed that the cumulative incidence of hepatic failure was
signiﬁcantly higher in patients having an APRI of >0.54 by
Kaplan-Meier testing (Fig. 1B). These data closely resembled the
results of Trivedi et al. that elevated APRI (>0.54) at diagnosis was
associated with a risk of disease progression, although our cohort
size was insufﬁcient to determine whether APRI or APRI-1y could
be independent prognostic markers of a response to UDCA.1444 Journal of Hepatology 20Liver biopsy in PBC is appropriate for certain patients [7] but
not always necessary for diagnosis. Speciﬁcally, a biopsy should
be considered in patients with atypical clinical presentation,
including AMA negativity, as described in EASL, AASLD, and
Japanese guidelines [7,8]. However, we routinely perform percu-
taneous liver biopsy, except in patients who are over 75 years of
age, have a short life expectancy due to comorbidities, or have
contraindications for a deﬁnitive diagnosis and important infor-
mation on disease stage and prognosis. We assessed the associa-
tion between APRI and histological stage and uncovered that the
numbers of patients with APRI >0.54 in Scheuer’s stage I, II, III,
and IV were 43 (35.8%), 21 (56.8%), 16 (76.2%), and 10 (100.0%),
respectively (p = 6.85  105, Fisher’s exact test). Furthermore,
APRI positively correlated with histological disease progression
(rs = 0.403, p = 1.01  108, Spearman’s rank correlation coefﬁ-
cient test) (Fig. 1C).
In conclusion, our ﬁndings agree closely with those of Trivedi
et al. [1] and strengthen the postulate that elevated APRI is asso-
ciated with an increased risk of disease progression in PBC. We
additionally revealed that APRI was related to histological pro-
gression in liver biopsy specimens. APRI appears to be a useful
tool in the clinical assessment of patients with PBC in multiple
ethnicities.
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Reply to: ‘‘AST/platelet ratio index associates with progression
to hepatic failure and correlates with histological ﬁbrosis stage
in Japanese patients with primary biliary cirrhosis’’
To the Editor:
We read with interest the letter by Joshita and colleagues
regarding our original article [1]. In taking the time to present
their important Japanese data [2], the authors provide further
independent validation of the AST/platelet ratio (APRI) in the risk
stratiﬁcation of patients with primary biliary cirrhosis (PBC). As
the authors surmise, the demography of our cohorts was varied
but was not representative of all populations globally, and the
robustness of any observation – even if simple and low cost as
in this case – is in validation more so than in discovery.
PBC is not a benign, homogeneous autoimmune liver disease;
and although present disease nomenclature needs improvement,
the current sole therapy – ursodeoxycholic acid (UDCA) – still
leaves a substantial cohort of individuals at risk from life-
threatening progressive disease and impaired quality of life. Risk
stratiﬁcation is therefore of value to identify individuals with
PBC who will beneﬁt from new treatments and as illustrated
herein, APRI at baseline or reapplied 1-year following therapy
(APRI-r1) represents an additive tool in identifying those patients
at risk of adverse clinical outcomewith high accuracy. Joshita et al.
also report good correlation between APRI and disease stage; [2]
however, it is apparent in both studies that a signiﬁcant propor-
tion of patients have an APRI >0.54 despite histological evidence
of early stage (I-II) disease. Moreover, in our study we were able
to show that in those without objective evidence of cirrhosis
APRI retains independent predictive value, thus supporting
APRI/APRI-r1 as a prognostic, clinically meaningful utility beyond
application as a surrogate for liver ﬁbrosis.
The ability to reliably predict outcome in patients with PBC is
beneﬁcial for patient counselling, timing of diagnostic proce-
dures, and therapeutic intervention. In this regard, prospective
evaluation of APRI-r1 in terms of additive value to existing UDCA
response criteria is of clear importance; particularly given the
potential use of surrogate end points in the development of
new treatments in PBC [3–5]. Our observations alongside those
of Joshita et al., further substantiate the role stratiﬁcation could
play, not just in clinical practice but also in clinical trial design.
Hence, future therapeutic trials in PBC should consciously con-
sider inclusion criteria beyond classic response criteria, and such
stratiﬁers may include additional tools such as liver elastography
and APRI-r1. Finally, as is evident from our studies, in the pursuit
of optimal management for a rare disease such as PBC, methodo-
logically robust, internationally representative, numerically well-
powered cohorts are essential in order to allow investigators to
make clear replicated observations about disease nature, course
and intervention.
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